Pharmaceutical Giants Shifted Toward Biotech Acquisitions
Biotech firms increasingly bypassed IPOs in 2026 as pharmaceutical companies pursued strategic mergers.
Updated on Sept. 25, 2026 in Biotech

Live Poll
Do you trust that pharmaceutical company acquisitions of biotech startups lead to better medical innovation?
Pharmaceutical companies have increasingly turned to acquiring biotechnology firms rather than allowing them to pursue initial public offerings. This trend defined the 2026 landscape for cell and gene therapy development.
Why it matters
Biotech companies often require the mature commercial infrastructure of larger pharmaceutical entities, while pharmaceutical firms seek the specialized innovation and risk-taking capacity inherent in smaller biotechnology ventures.
In 2025, biotech IPOs raised $3 billion, a decline from $4 billion in 2023. Meanwhile, 2026 saw significant deals, including Eli Lilly committing a $3.25 billion upfront payment for Kelonia Therapeutics.
The players
Eli Lilly
Eli Lilly is a global pharmaceutical corporation that reported $65 billion in 2025 revenue and projects $90 billion for 2026.
AstraZeneca
AstraZeneca is a multinational pharmaceutical firm that agreed to pay $425 million for EsoBiotec in 2026.
AbbVie
AbbVie is a research-based biopharmaceutical company that completed its $2.1 billion purchase of Capstan Therapeutics in August 2026.
Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical firm that agreed to pay $1.5 billion for Orbital Therapeutics in October 2026.
The details
Pharmaceutical companies are now acquiring biotech firms at development stages that historically marked the traditional IPO window. Firms like Eli Lilly are utilizing massive revenue streams to consolidate specialized platforms directly into their pipelines.
Timeline
Astellas acquired Ocata Therapeutics in 2016.
Gilead Sciences bought Kite Pharma for $11.9 billion in 2017.
Biotech IPOs raised $4 billion in 2023.
Biotech IPOs raised $3 billion in 2025.
Pharmaceutical M&A activity accelerated throughout 2026.
The Tech Race
This wave of consolidation follows the precedent set by the 2017 Gilead Sciences acquisition of Kite Pharma. Current industry strategies now prioritize direct integration over independent public listings to secure next-generation cell and gene therapy platforms.
Investors and consumers may see changes in treatment availability as specialized innovations move from independent labs to large-scale pharmaceutical pipelines. These mergers can streamline access to advanced therapies but may also reduce the number of independent firms available for public investment.
The takeaway
The shift toward acquisition suggests that major pharmaceutical players are increasingly confident in their ability to scale biotech innovation internally. Stakeholders should track these consolidation patterns as they indicate which specific therapeutic platforms are deemed most commercially viable.
Further reading
For more on industry trends, visit Biotech.
Source note: This article includes information reported by BioXconomy.
Live Poll
Do you trust that pharmaceutical company acquisitions of biotech startups lead to better medical innovation?



